HUMATROPE 5 mg.

Active substance
Somatropin
Humatrope
ATC:
H01AC01 Somatropin
Therapeutic
Hormones of the hypothalamus, pituitary and their antagonists
Nosological classification (ICD-10)
Stunting E34.3 [dwarfism] nec
Q96 Turner's syndrome
Structure and composition
Lyophilized powder for injection in vials of 4 IU, together with the solvent into the vial with 2 ml or excipients for injectable pens Humatropen II 18 and 36 IU / ml, together with a solvent.
Features
Biosynthetic recombinant human growth hormone polypeptide chain comprises amino acid residue 191 (in the sequence identity with human growth hormone).
Pharmacological Action
Mode of action - anabolic hyperglycemia.
Stimulates bone growth, increases the number and size of muscle cells, mobilized fat slows sodium, potassium, phosphorus.
Indications drug Humatrop
Growth disturbance with growth hormone deficiency, Turner syndrome.
Contraindications
Hypersensitivity (including m-cresol and glycerin) closed epiphyseal tumor active process, carrying out the anti-tumor therapy, signs of tumor growth of acute intracranial injury period.
Side effects of the drug Humatrop
Hyperglycemia, impaired glucose tolerance, Syndrome transient edema symptoms of hypothyroidism.
Cooperation
Glucocorticoids weaken effect.
Dosing and Administration
V / M, N / A. The dosage and timing of administration selected individually (0.48 IU / kg per week). When growth hormone deficiency - 0.48 IU / kg per week in syndrome Turner - 0.8-0.9 IU / kg, equivalent to 24-28 IU / m body surface area weekly. Weekly dose is divided into 6-7 injections and administered in the evening. During long-term treatment, it is necessary to control the concentration of glucose in blood and the thyroid hormones.
Storage conditions of the drug Humatrop
List B :. At 2-8 ° C. The resulting solution is stable for 21 days at 2-8 ° C Do not freeze.
Shelf life Humatrop ™
2 years